Advances and challenges: dendritic cell vaccination strategies for glioblastoma
Introduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cel...
Main Authors: | Teilo H. Schaller, John H. Sampson |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14760584.2016.1218762 |
Similar Items
-
Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma
by: Robert C. Subtirelu, et al.
Published: (2023-10-01) -
Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial
by: Guilherme Lepski, et al.
Published: (2023-02-01) -
Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
by: Salvatore Cozzi, et al.
Published: (2022-02-01) -
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
by: Kyu-Won Lee, et al.
Published: (2023-08-01) -
Current state and prospects of using dendritic cell vaccination for cancer immunotherapy
by: I.Yu. Filin, et al.
Published: (2022-09-01)